Expression of BCL-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy
1996

BCL-2 Expression in Node-Negative Breast Cancer

Sample size: 441 publication Evidence: moderate

Author Information

Author(s): H-J van Slooten, PC Clahsen, JH van Dierendonck, Ch Duva, C Pallud, A-M Mandard, A Delobelle-Deroide, CJH van de Velde, MJ van de Vijver

Primary Institution: Leiden University Hospital

Hypothesis

Does BCL-2 expression predict response to chemotherapy in node-negative breast cancer patients?

Conclusion

BCL-2 expression is associated with favorable prognosis but does not predict response to chemotherapy.

Supporting Evidence

  • High BCL-2 expression correlates with estrogen and progesterone receptor positivity.
  • Patients with high BCL-2 expression had better disease-free and overall survival.
  • BCL-2 expression does not predict response to chemotherapy in this patient group.

Takeaway

This study looked at how a protein called BCL-2 affects breast cancer treatment. It found that while high levels of BCL-2 are linked to better outcomes, they don't help doctors know if chemotherapy will work.

Methodology

The study used immunohistochemistry to assess BCL-2 expression in tumor samples from premenopausal, lymph node-negative breast cancer patients who were randomized to receive chemotherapy or not.

Limitations

BCL-2 was not found to be an independent prognostic factor in multivariate analysis.

Participant Demographics

Premenopausal women with node-negative early breast cancer.

Statistical Information

P-Value

P=0.004 for disease-free survival, P=0.009 for overall survival

Confidence Interval

95% CI 0.35-1.06

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication